Therapy Areas: Vaccines
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
3 April 2024 -

Immunotherapy company BioVaxys Technology Corp (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) reported on Wednesday that it has secured a Notice of Allowance from the United States Patent and Trademark Office for a patent enabling antibody immune response through low dose volume delivery of a B-cell epitope with its DPX formulation. This patent, part of BioVaxys' Intellectual Property portfolio, complements its existing international patent applications.

DPX, BioVaxys' lipid-based delivery platform, facilitates robust and sustained immune responses without an aqueous component. It can be combined with various antigens, proteins, peptides, mRNA, or small molecules, attracting antigen-presenting cells to the injection site for enhanced efficacy.

The company aims to deliver B-cell epitopes in doses as low as 50µL to 90 µL, significantly smaller than existing vaccine volumes. B-cell epitopes play a crucial role in activating the immune system's response against pathogens by binding to corresponding antigen receptors.

Additionally, BioVaxys has initiated the national phase for DPX SurMAGE, a dual-targeted immunotherapy formulation containing tumour-associated antigens survivin and MAGE A9. These antigens are prevalent in various cancers and represent promising targets for cancer vaccines.

Following a successful Phase I clinical study in Canada focusing on bladder cancer patients, DPX SurMAGE demonstrated a robust peptide-specific T cell response. The company plans further development in collaboration with clinical study investigators.

BioVaxys Technology Corp is dedicated to developing novel immunotherapies using its DPX immune-educating technology platform and HapTenix 'neoantigen' tumour cell construct platform. Its clinical pipeline includes maveropepimut-S and BVX-0918, targeting advanced cancers such as Relapsed-Refractory Diffuse Large B Cell Lymphoma and platinum-resistant ovarian cancer. Additionally, BioVaxys leverages its tumour immunology expertise to identify new targetable tumour antigens for personalized immunotherapeutic vaccines.